GD2.CAR-triVSTs

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameGD2.CAR-triVSTs

Drug Alias NameGD2.CAR-triVSTs

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionDisialoganglioside GD2 modulatorsT lymphocyte replacements

TargetsDisialoganglioside GD2

Therapy Area/IndicationsNeuroblastoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesBaylor College Of Medicine

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesMethodist Hospital System Texas Children'S Hospital Baylor College Of Medicine

Active IndicationsN/A

Inactive IndicationsNeuroblastoma

Other Information

ATC CodeN/A